Replies to post #167091 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Still stands at 10 active sites.

[nidan7500]

Jj:

If calculated, it will add to his chess master status and help confirm that everything he's doing and has been doing has been part of a larger plan. It will allow us to be even more patient and trusting in his ability.

IMO, we seeing a process of communication through public venues/presentations that appear to be carefully thought through in sequence and content.

[F1ash]

If the poster does reveal some novel info for our Alz trial that the company didn't want released prior to the CTAD, it will answer the question: Was Missling sloppy or calculated in regard to the registration?

If calculated, it will add to his chess master status and help confirm that everything he's doing and has been doing has been part of a larger plan.

“In 2004 the International Committee of Medical Journals Editors (ICMJE, including editors of the Medical Journal of Australia, Lancet, New England Journal of Medicine and others) declared that they would not consider a trial for publication without evidence that it had been registered in a publicly accessible trials registry prior to enrolment of the first participant.

The Declaration of Helsinki now explicitly states that "every clinical trial must be registered in a publicly accessible database before recruitment of the first subject".
The Declaration is the cornerstone document guiding the ethical conduct of research in humans by physicians.
The World Health Organization (WHO) considers the registration of all interventional trials to be "a scientific, ethical and moral responsibility" (who.int/ictrp/en/).
Australia has also endorsed prospective trial registration in two key documents which guide the conduct of Human Research Ethics Committees and the conduct of Australians undertaking research in humans.

The 2007 revision of the National Statement on Ethical Conduct in Human Research contains clause 3.3.12 which states "Before beginning the clinical phase of the research, researchers should register clinical trials in a publicly accessible register".

(Today’s date September 28, 2018)


“NEW YORK – August 28, 2018 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that it has enrolled the first patient in its Phase 2b/3 double-blind, randomized, placebo-controlled, 48-week safety and efficacy trial of ANAVEX®2-73 for the treatment of early Alzheimer’s disease.
The Phase 2b/3 study will enroll approximately 450 patients, randomized 1:1:1 to two different ANAVEX®2-73 doses or placebo. As part of the planned international study, North American sites will be added.

“We are very excited to have now commenced the study, having enrolled our first patient.”




http://www.anzctr.org.au/TrialSearch.aspx?searchTxt=Anavex&conditionCategory=&conditionCode=&interventionCodeOperator=&interventionCode=&ageGroup=&healthyVolunteers=&gender=&allocationToIntervention=&dateOfRegistrationFrom=&dateOfRegistrationTo=&trialStartDateFrom=&trialStartDateTo=&recruitmentCountryOperator=&countryOfRecruitment=&primarySponsorType=&fundingSource=&healthCondition=&interventionDescription=&phase=&recruitmentStatus=®istry=ðicsReview=&studyType=&isBasic=True&postcode=&distance=



https://www.australianclinicaltrials.gov.au/search/node/Anavex


https://clinicaltrials.gov/ct2/results?cond=&term=Anavex&cntry=&state=&city=&dist=